Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Free Report) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totalling 216,500 shares, an increase of 36.4% from the July 15th total of 158,700 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average trading volume of 211,400 shares, the days-to-cover ratio is presently 1.0 days.
Institutional Trading of Lexaria Bioscience
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC acquired a new stake in shares of Lexaria Bioscience in the 2nd quarter valued at about $2,836,000. Cowen AND Company LLC purchased a new stake in Lexaria Bioscience in the fourth quarter valued at approximately $320,000. Welch Group LLC acquired a new stake in shares of Lexaria Bioscience in the first quarter valued at approximately $87,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Lexaria Bioscience during the second quarter worth approximately $63,000. Institutional investors and hedge funds own 13.06% of the company’s stock.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Lexaria Bioscience in a report on Thursday, July 18th.
Lexaria Bioscience Price Performance
Shares of NASDAQ:LEXX traded down $0.06 during trading on Thursday, hitting $3.15. 120,106 shares of the company were exchanged, compared to its average volume of 315,612. The firm’s 50 day moving average price is $3.06 and its 200-day moving average price is $3.02. Lexaria Bioscience has a 12-month low of $0.84 and a 12-month high of $6.85. The stock has a market capitalization of $40.59 million, a P/E ratio of -7.16 and a beta of 0.99.
Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) last announced its quarterly earnings results on Friday, July 12th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.04). The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.15 million. As a group, equities research analysts anticipate that Lexaria Bioscience will post -0.42 EPS for the current year.
About Lexaria Bioscience
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.
Further Reading
- Five stocks we like better than Lexaria Bioscience
- What are earnings reports?
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Jeff Brown’s Exegesis AI Stock Picks
- The Role Economic Reports Play in a Successful Investment Strategy
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.